SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.

SD BioSensor, Inc

SD BIOSENSOR is involved in the development and supply of diagnostic reagents, providing platforms for various tests including screening and confirmation tests. Self-described as a global leader in the field.

SD BIOSENSOR

SD BIOSENSOR INC | 8,537 followers on LinkedIn. Continuous technological innovations for a global number 1 in-vitro diagnostics company | Continuous technological innovations for a global number 1 in-vitro diagnostics company

Assistant Product Manager -CGMS & BGMS(India) at SD Biosensor Gurgaon

Sandeep Sharma

Joohan Kim

Healthcare- Devices | FMCG | RSM-Upper North |Leadership| Sales-Strategy | Marketing & Sales Management| PGDM in Core Marketing.

Virendra Singh

Regional Sales Manager at SD BIOSENSOR INC

Amit Jaiswal

SD BIOSENSOR INC

Beauty of Cutting Edge POCT Molecular System #M10 #SDBIOSENSOR

Here we go again🌞Guten Morgen von der #GNPI -DGPI-WAKKA Tagung 2024! Martina Dannecker , Steffen Hohmann , Scarlett Lee, André Marques , Gabriele Molitor & Tony Sung freuen sich auf ihren Besuch! #GNPIDGPIWAKKA2024 #neonatologie #frühgeborenenmedizin #infektologie #frühchen #kinderintensiv #Gesundheitswesen #medizin #arzt #krankenhaus #klinik #sdbiosensor

bestbion dx GmbH

SD BIOSENSOR INC will be present at the 34th ECCMID in Barcelona, come to visit our stand!

Relab - molecular innovation

Wir freuen uns auf der diesjährigen #GNPI -DGPI-WAKKA Tagung dabei zu sein! Besuchen Sie auch unser Lunchsymposium - Patientennahe Diagnostik: #POCT in Klinik und Praxis - 👉 https://lnkd.in/eHsYE_UG ? Unser Team, Martina Dannecker , Steffen Hohmann , André Marques & Gabriele Molitor freut sich auf ihren Besuch auf unserem Messestand (Stand-Nr. 14)! #GNPIDGPIWAKKA2024 #neonatologie #frühgeborenenmedizin #infektologie #frühchen #kinderintensiv #Gesundheitswesen #medizin #arzt #krankenhaus #klinik

Yep, Messe-Saison is upon us 😉 Danke an Silke König ! Für uns vor Ort @ 32. BÄMI-Frühjahrstagung 2024! #Gesundheitswesen #medizin #medizintechnik #biotechnologie #arzt #krankenhaus #klinik #immunoassay #biomarker #mikrobiologie #molekulardiagnostik

Und los geht´s für uns auf dem diesjährigen Prospitalia Kongress 2024 🎉 -Stand E1.05- Steffen Hohmann & Andreas Rohrmoser freuen sich auf ihren Besuch! #Gesundheitswesen #PSKongress2024 #medizin #medizintechnik #biotechnologie #arzt #krankenhaus #klinik #immunoassay #biomarker #mikrobiologie #molekulardiagnostik #sdbiosensor

Why is a dual rapid diagnostic test for HIV and syphilis better than two separate tests? In low- and middle-income countries: 🩸 70-100% of pregnant women are screened for HIV 🩸 40-60% of pregnant women are screened for syphilis By testing for both conditions with one test, health providers can integrate syphilis testing with HIV testing programmes, which have high testing rates built on well-established guidelines and processes. Proud to partner with SD BIOSENSOR INC and the Clinton Health Access Initiative, Inc. . https://lnkd.in/eMukYXrv

MedAccess

Last week, Brazil started training healthcare workers on the appropriate administration of tafenoquine - guided by quantitative G6PD testing - to treat P. vivax #malaria . Testing for G6PD deficiency is essential for treating P. vivax malaria. Patients who are G6PD deficient are at risk of hemolytic anaemia during treatment with the recommended 8-aminoquinoline class of drugs to clear the liver stage infection. As a result, healthcare workers often prescribe lowers doses of 8-aminoquinoline drugs over a longer period. This often leads to poor adherence as patients stop treatment when they feel better, although the infection persists in their liver. Access to G6PD testing helps health workers care for their patients. Brazil has committed to rolling out the tests alongside single-use tafenoquine. This is a major step forward in the fight against P. vivax malaria. #WHWWeek | #SafeSupportedHealthWorkers | SD BIOSENSOR INC | PATH

Visita il nostro nuovo fantastico sito web www.relabsrl.it SD BIOSENSOR INC Relab - molecular innovation

1373

COM:SDBIOSENSOR

SD BIOSENSOR

Last Close

10,190.00

22/11 06:30

Market Cap

1.11T

Beta: -

Volume Today

283.29K

Avg: -

Financials Not Available